Skip to content
Contact
Careers
About Us
Epigenetic Regulation
Clinical Development
Partnering & Technologies
Investors
Menu Toggle
Overview
News
SEC Filings
Stock Information
Events
FAQs
Corporate Governance
Resources
Main Menu
AASLD: Durect’s alcoholic hepatitis med repairs liver, cuts mortality in phase 2
Post navigation
←
Previous Resource
Next Resource
→
About Us
Menu Toggle
Overview
Leadership
Board of Directors
Epigenetic Regulation
Menu Toggle
Overview
Larsucosterol
How it Works
Broad Therapeutic Potential​
Clinical Development
Menu Toggle
Clinical Trials
Pipeline
Alcohol-Associated Hepatitis (AH)
Nonalcoholic Steatohepatitis (NASH)
Partnering & Technologies
Menu Toggle
Overview
Long-Acting Injectables
ALZET Osmotic Pumps
Current Collaborations
Investors
Menu Toggle
Overview
News
SEC Filings
Stock Information
Events
FAQs
Corporate Governance
Resources
Menu Toggle
Publications
Factsheets
Contact
Careers
About Us
Menu Toggle
Overview
Leadership
Board of Directors
Epigenetic Regulation
Menu Toggle
Overview
Larsucosterol
How it Works
Broad Therapeutic Potential​
Clinical Development
Menu Toggle
Clinical Trials
Pipeline
Alcohol-Associated Hepatitis (AH)
Nonalcoholic Steatohepatitis (NASH)
Partnering & Technologies
Menu Toggle
Overview
Long-Acting Injectables
ALZET Osmotic Pumps
Current Collaborations
Investors
Menu Toggle
Overview
News
SEC Filings
Stock Information
Events
FAQs
Corporate Governance
Resources
Menu Toggle
Publications
Factsheets
Contact
Careers
Scroll to Top